IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:

Landau et al.

Confirmation No.: 1508

1614

Appl. No.:

10/805,977

Group Art Unit: Examiner:

Not yet assigned

March 22, 2004

METHODS OF TREATING LOWER URINARY TRACT DISORDERS

USING $\alpha_2\delta$ SUBUNIT CALCIUM CHANNEL MODULATORS WITH

SMOOTH MUSCLE MODULATORS

September 29, 2004

fil Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

SUPPLEMENTAL CITATION UNDER 37 C.F.R. § 1.97

Attached is a Supplemental Form PTO-1449 listing several documents that were first cited in the International Search Report for the corresponding International Application Numbers PCT/US2004/008605 and PCT/US2004/008701 not more than three months prior to the filing of this Statement. In this regard, Applicant notes that the International Search Report was not received by any individual designated by 37 CFR 1.56(c) more than thirty (30) days prior to the filing of this Information Disclosure Statement.

The Search Report is enclosed. In accordance with the Office waiver published July 11, 2003, copies of the cited U.S. patents and patent application publications are not enclosed. Applicant does enclose copies of any cited foreign patent documents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

It is requested that the Examiner consider these documents and officially make them of record in accordance with the provisions of 37 C.F.R. § 1.97 and Section 609 of the MPEP. By submitting the listed documents, Applicant in no way makes any admission as to the prior art status of the listed documents, but is instead submitting the listed documents for the sake of full disclosure.

Respectfully submitted,

Registration No. 47,549

CUSTOMER No. 00826 ALSTON & BIRD LLP Bank of America Plaza

101 South Tryon Street, Suite 4000 Charlotte, NC 28280-4000 Tel Raleigh Office (919) 862-2200

Fax Raleigh Office (919) 862-2260

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA

22313,1450, on September 29, 2004

o Pixlev

		7		Complete if Known						
Substitute for form 1449/PTO (Revised 04/2003) OCT 0 1 2004 OCT 0 1 20				Application Number 10/805,977						
				Filing Date			March 22, 2004			
				First Named Inventor			Landau			
				Group Art Unit			1614			
STAT	EME	NT BY APPLICANT								
	(Use as m	any sheets as necessary)		Examiner Name			Not yet assigned			
Sheet	1	of 1		rney Dock			046562/2746	60		
			J . S. PA	TENT D	OCUM.	1ENT	<u></u>			
Examiner Initials*	Cite No.	· · · · · · · · · · · · · · · · · · ·		Publication Date MM-DD-YYYY A ₁		Name of Patentee or Applicant of Cited Document		Pages, Columns, Lines, Where Relevant Passages of Relevant Figures Appear		
		US-							преш	
	· · · · · · · · · · · · · · · · · · ·			PATENT	DOC	UME	ENTS			
Examiner	Cite	Foreign Patent Document		Publication Date		Name of Patentee or		Pag	Pages, Columns, Lines, Where Relevant	English Language
Examiner	No.	Country Code - Number Kind Code (if known)		MM-DD-YYYY		Applicant of Cited Document		Pa	Passages or Relevant Figures Appear	Translation Attached
	30	WO 96/37202	1	11-28-1996		Alza Corporation				
	31	WO 01/01983 A1	0	01-11-2001		Warner-Lambert Company				
	32	WO 01/24792 A1		04-12-2001		Warner-Lambert Company				
	33	WO 01/37832 A2	0	05-31-2001		Aventis Pharma S.A.				
	34	WO 03/000642 A2	0	01-03-2003		NICO	X S.A.			
	35	WO 03/070237		08-28-2003		Warne Comp	er-Lambert any			
	36	WO 2004/054560 A1		07-01-2004		Warner-Lambert Company				
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.							English Language Translation Attached	
	37	DE SARRO, G., et al., "Gabapentin Potentiates the Antiseizure Activity of Certain Anticonvulsants in DBA/2 Nice", European Journal of Pharmacology, 1998, pp. 179-185, Vol. 349.								
	38	FELIX, R., "Voltage-Dependent Ca ²⁺ Channel α ₂ δ Auxiliary Subunit: Structure, Function and Regulation", <i>Receptors and Channels</i> , pp. 351-361, Vol. 6.								
	39	FIELD, M.J., et al., "Gabapentin and the Neurokinin ₁ Receptor Atagonist Cl-1021 Act Synergistically in Two Rat Models of Neuropathic Pain", Journal of Pharmacology and Experimental Therapeutics, 2002, pp. 730-735, Vol. 303.								
	40	KATZING, B.G., "Basic and Clinical Pharmacology," Lange Medical Books, p. 457, column 2, last paragraph.								
	41	OBERPENNING, F., et al., "Interstitial Cystitis: An Update", Current Opinion in Urology, 2002, pp. 321-332, Vol. 12								
		1				 _	Date			<u> </u>

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.